Navigation Links
Celling Biosciences Received CE Mark Approval for ART PRP and ART BMC Systems
Date:6/16/2017

With an aging global population and rising dangers of opioid addiction and complications, demand for platelet-rich plasma and bone marrow concentrate based treatments has been steadily rising in the United States. According to the Global Regenerative Medicine Market 2016-2020 report, the specialty of regenerative medicine is forecasted to grow at a CAGR of 20.7%. Hank Brown, Celling Biosciences Executive Vice President of Sales, stated, “The CE Mark approval allows the company to respond to the growing opportunity in international markets, particularly within Europe, so this achievement is an important milestone in the company’s sales history and a strategic step in the company’s continued growth.”

The ART PRP and ART BMC are class-leading, sterile-packaged disposable devices that are used to concentrate a sample of a patient’s blood or bone marrow into their subcomponents through centrifugation. The concentration process takes less than 30 minutes at point-of-care and is often done on an outpatient basis depending on the procedure being performed. As peer-reviewed and presented at the Tissue Engineering and Regenerative Medicine International Society Annual Meeting (Sept 2015, Boston, MA), the ART BMC and ART BMC Plus devices consistently recovers 90% of concentrated autologous stem and progenitor cells, platelets, and growth factors – performance that is unrivaled in the world.

Also, unique to Celling Biosciences, the ART BMC and ART PRP systems have an optional, proprietary integrated filter system which allows physicians to further concentrate the patient’s platelet-rich plasma (PRP) or platelet-poor plasma (PPP) without any additional sterile breaks. In vitro studies have shown the filter system’s ability to concentrate proteins like alpha-2-macroglobulin (A2M), interleukin 1 receptor antagonist protein (IRAP), and fibrinogen.

Physicians can utilize the components of their choice to treat various orthopedic applications, employing ART PRP or ART BMC devices on average once every 42 minutes in the United States. The Celling Biosciences international business development team believes this level of usage will more than quadruple in the next year now that the European market is open for the ART family of products.

Kevin Dunworth, Celling Biosciences Founder and CEO, commented, “As the only company on the market with a cell-centric approach to all of our product lines, the development and commercialization of our proprietary ART PRP and ART BMC systems have been years in the making. Today is a proud moment for our company as we expand into the European market.”

About Celling Biosciences:
As the innovative leader in regenerative medicine, Celling Biosciences collaborates with physicians and scientists to develop the most sophisticated technologies and techniques for maximizing the collection, concentration, and delivery of autologous blood and bone marrow aspirate.

Read the full story at http://www.prweb.com/releases/2017/06/prweb14432785.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Adept Sound Has Announced the Market Launch of Innovative New Noise Cancelling Silicone Ear Plugs
2. Celling Biosciences Announces New Location in Austin, Texas
3. ACEA Biosciences, Inc. to be featured in Upcoming Episode of Innovations with Ed Begley, Jr.
4. INDIGO Biosciences Now Offers PXR
5. Sharp Edge Labs and Creagen Biosciences Enter Drug Discovery Collaboration
6. Wayne State opens new $93 million biosciences center aimed at eliminating health disparities in Detroit
7. GD Biosciences Announces Availability of the PULs Cardiac Test in India as Part of International Expansion
8. Vortex Biosciences Announces Publication in Oncotarget That Demonstrates the Value of Combining CTCs and cfDNA in Assessing Cancer Patient Disease
9. Vortex Biosciences Selected as Finalist for 2017 SLAS Innovation Award
10. Pierian Biosciences Names Mark S. Gelder, MD as Chief Medical Officer
11. Vortex Biosciences Announces Publication in Nature Communications Describing the First Single Cell Western Blot for Circulating Tumor Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... ... 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out ... free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting ... children of all ages; it is a non-competitive, non-timed event, which is all about ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... 12, 2017 , ... Planet Fitness, one of the largest and fastest growing ... open a flagship location in Covington, LA at 401 N. U.S. Highway 190, in ... to Office Depot in the Holiday Square shopping center. Its location allows it to ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology: